• 4DMedical receives A$5.5m via a Placement at A$0.425 per share
• Strong support from new and existing institutional investors
• Proceeds to be used for commercialisation and general working capital
• Company to offer A$7m underwritten Share Purchase Plan (SPP)

4DMedical Limited, a respiratory imaging technology company, has announced that it has completed a share placement (Placement) to institutional and sophisticated investors, raising approximately A$5.5 million in gross proceeds. The Placement will result in the issue of approximately 12.9 million shares at A$0.425 per share, within the Company's existing placement capacity. The issue price represents a 22.7% discount to the last closing price. In addition to the Placement, the Company will also offer Eligible Shareholders in Australia and New Zealand the opportunity to participate in a Share Purchase Plan (SPP), targeting an additional A$7 million in gross proceeds. The SPP will allow Eligible Shareholders to purchase between $1,000 and $30,000 worth of new shares at an offer price being the lower of A$0.425 per share or a 2.5% discount to the VWAP of shares traded on the ASX during the five trading days up to the closing date of the SPP. The proceeds from the Placement and SPP will be applied towards the Company's commercialisation requirements and for general working capital. Subject to shareholder approval, participants in the Placement and SPP will also receive 1 unlisted attaching option, exercisable at A$0.55, for each share issued. Upon exercise of the New Options, the holder will receive one ordinary share and one piggyback option exercisable at A$0.75, which the Company seeks to apply for official quotation.

The Company is experiencing strong growth in the number of sites, the number of scans per site and the revenue earned per scan. The full might and scale of the Philips sales team will provide another layer of growth to the Company's organic growth. Later in the year, as CT:VQ™ comes online, the Company gains another dramatic catalyst for growth, as CT:VQ™ is set to disrupt a billion dollar segment of respiratory diagnostics by displacing Nuclear VQ imaging with a technology that is faster, safer, cheaper, more convenient and more accessible.